Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Shoulder Innovations reported Q3 2026 revenue of $16.2 million, a 38% year-over-year increase driven by higher implant system sales and surgeon adoption. The company raised its full-year 2026 revenue guidance to a range of $68 million to $70 million and highlighted the commercial launch of its N-22 humeral head.
“Our third quarter results reflect the consistency of our commercial model, as we added new surgeons ahead of plan, grew volume within our existing customer base, and kept our product roadmap moving.”
Rob Ball, CEO of Shoulder Innovations
“This performance enabled us to again raise our outlook for the full year, and confirmed our conviction regarding our ability to grow market share through a differentiated approach to shoulder surgical care.”
SkinHealth Systems reported third quarter 2026 financial results, with net sales of $69.2 million and a significantly narrowed net loss of $0.9 million compared to $11.0 million in the prior year. The company highlighted a return to growth in consumables and improved adjusted EBITDA margins as it executes on strategic priorities for its flagship Hydrafacial brand.
Term
Q3 2026
“Our third quarter results reflect encouraging progress in strengthening our business. Revenue trends improved, consumables returned to growth, and we delivered healthy adjusted EBITDA performance. While we have more work ahead, these results give us greater confidence that the actions we are taking are moving the business in the right direction.”
Pedro Malha, President and Chief Executive Officer
Sweetgreen reported third quarter 2026 revenue of $176.0 million, a 2.1% increase year-over-year, despite a same-store sales decline of 6.4%. The company narrowed its net loss to $30.7 million compared to $36.1 million in the prior year period, though restaurant-level profit margins compressed to 10.4% due to traffic deleverage and higher labor costs.
Term
Q3 2026
“We believe our Sweet Growth Transformation Plan is beginning to take hold, with sales improving through the quarter and positive comparable sales in October, primarily driven by transaction growth. We are confident in our plan to build on this progress by investing in our restaurant teams, delivering a consistently great customer experience and expanding our menu with bold, craveable food. Our focus is clear: bring more customers into sweetgreen and give them more reasons to come back.”
Jonathan Neman, Co-Founder and Chief Executive Officer
Planet Fitness reported a decrease in cash and cash equivalents to $310.2 million as of September 30, 2026, compared to $345.7 million at year-end 2025. The company maintained a strong asset base with total current assets of $604.4 million and significant investments in property, equipment, and right-of-use assets totaling over $1 billion.
Enliven Therapeutics reported a significant increase in liquidity, with cash, cash equivalents, and marketable securities totaling approximately $884.4 million as of September 30, 2026, compared to $462.6 million at year-end 2025. The company is advancing its clinical pipeline, specifically relcobatinib (ELVN-001), and preparing for the ENABLE-2 Phase 3 pivotal trial.
Westwood Holdings Group reported total revenues of $26.6 million for the third quarter of 2026, an increase from $24.3 million in the prior year, driven by higher asset-based advisory fees. Net income attributable to the company was $3.1 million for the quarter, down slightly from $3.7 million in 2025 due to increased employee compensation and professional services expenses.
Westwood Holdings Group reported Q3 2026 revenue of $26.6 million and net income of $3.1 million, driven by growth in its ETF platform and private capital business. The company also declared a quarterly cash dividend of $0.15 per share and highlighted the launch of its PWRX ETF on the Texas Stock Exchange.
Term
Q3 2026
“We're proud of the progress we made this quarter, highlighted by the launch of our Enhanced Power and Infrastructure ETF (PWRX) as the first new ETF on the Texas Stock Exchange and our ETF platform surpassed $430 million in assets at quarter-end. With continued momentum in our private capital business and a robust pipeline across our Value, Managed Investment Solutions and Energy strategies, we believe Westwood is well positioned to deliver long-term value for clients and shareholders.”
Puma Biotechnology reported Q3 2026 financial results with total product revenue of $54.1 million, driven by sales of NERLYNX. The company reported GAAP net income of $6.0 million and raised its full-year 2026 net income guidance while continuing to advance its alisertib clinical development programs.
Term
Q3 2026
“Third quarter U.S. NERLYNX sales were positively impacted by increased year-over-year demand and were negatively impacted by higher than expected gross to net due to an increase in Medicaid and 340B sales, as well as a delay in sales to Puma’s ex-U.S. commercial partners that shifted from the third quarter to the fourth quarter.”
Alan H. Auerbach, Chairman, Chief Executive Officer and President
“We continue to anticipate increased year-over-year demand for NERLYNX, while we continue to advance alisertib across our ALISCA® clinical development programs.”
Alan H. Auerbach, Chairman, Chief Executive Officer and President
Eton Pharmaceuticals reported record Q3 2026 revenue of $57.9 million, representing 158% year-over-year growth and surpassing its $200 million annualized revenue run rate goal ahead of schedule. The company achieved a 49% Adjusted EBITDA margin and raised its full-year 2026 revenue guidance to over $175 million.
Term
Q3 2026
“Eton delivered another record quarter, with revenue of $57.9 million, up 158% year over year, and surpassed our $200 million annualized revenue run rate goal five quarters ahead of schedule. The team also demonstrated exceptional operational execution, significantly expanding margins, and delivering an adjusted EBITDA margin of 49%.”
Sean Brynjelsen, CEO of Eton Pharmaceuticals
“We have also made transformational improvements to our pipeline in recent months with ASN-001 for infantile hemangiomas, and ET-900, our new program evaluating mecasermin in infantile and epileptic spasms.”
A10 Networks reported record third quarter 2026 revenue of $91.5 million, up 22.6% year-over-year, driven by broad-based demand for networking and security solutions. The company updated its full-year 2026 revenue growth guidance to 16% and set a long-term 2029 revenue target of $500 million. Additionally, the Board approved a quarterly cash dividend of $0.06 per share.
Term
Q3 2026
“Third quarter revenue increased 22.6% year-over-year to record quarterly levels, supported by broad-based customer demand, with our business model enabling record non-GAAP operating and net income levels.”
Dhrupad Trivedi, President and Chief Executive Officer of A10 Networks
“Our progress, expanding global opportunity and continued execution give us confidence in setting long-term targets of $500 million in annual revenue through organic growth and $2.00 in annual non-GAAP EPS for fiscal year 2029.”
Dhrupad Trivedi, President and Chief Executive Officer of A10 Networks
Adicet Bio reported third quarter 2026 financial results and provided updates on its clinical pipeline, including positive Phase 1 data for prula-cel in systemic lupus erythematosus. The company ended the quarter with $204.4 million in cash and cash equivalents, providing a projected runway into the second half of 2027.
Term
Q3 2026
“The growing body of evidence for prula-cel continues to strengthen our conviction in its potential to generate meaningful, lasting remissions for patients living with SLE, including those with LN and extra renal SLE. The compelling efficacy observed following complete discontinuation of immunosuppressants, together with evidence of a deep immune reset and a favorable safety profile supporting outpatient administration, reinforce the potential for prula-cel to meaningfully change the treatment paradigm for lupus patients.”
Chen Schor, President and Chief Executive Officer of Adicet Bio
Kodiak AI reported third-quarter 2026 results, highlighting that its Autonomy Readiness Measure reached 99% ahead of its targeted year-end unsupervised autonomous long-haul launch. The company secured a landmark binding agreement with DTL Transport for 75 customer-owned unsupervised autonomous trucks and named IKEA Supply as its first long-haul launch partner.
“We are approaching a defining moment for Kodiak as we advance toward our targeted year-end unsupervised autonomous long-haul launch, with our Autonomy Readiness Measure now at 99%. Our landmark binding agreement with DTL Transport to deploy the Kodiak Driver in 75 customer-owned and operated unsupervised autonomous trucks represents a significant commercial commitment to our Driver-as-a-Service model and demonstrates growing customer confidence in Kodiak's technology and commercial capabilities.”
Assurant, Inc. reported a net income of $275.2 million for the third quarter of 2026, up from $265.6 million in the prior year period. Total revenues grew to $3.53 billion, driven by increases in net earned premiums and fee income, while the company maintained a strong balance sheet with total assets of $36.49 billion.
Adicet Bio, Inc. is a clinical-stage biotechnology company focused on gamma delta T cell therapies for autoimmune diseases and cancer, with its lead candidate prula-cel (ADI-001) currently in Phase 1 trials. The company reported 9,361,596 shares of common stock outstanding as of November 3, 2026, and highlighted significant risks including the need for substantial additional financing and reliance on third-party manufacturing.
Citizens, Inc. reported third quarter 2026 financial results, highlighted by a 7% increase in direct insurance premiums to $50 million. The company reported a net loss of $0.4 million compared to a net income of $2.4 million in the prior year period, primarily due to higher future policy benefit reserves and a tough comparison against reserve releases in 2025.
“Premium growth, distribution expansion, and cash generation all continued to strengthen. Our third-quarter results show the continued momentum of our domestic insurance business. Overall direct premiums grew 7% to $50 million, led by a 9% increase in direct first year premiums, as our final expense sales and expanding domestic distribution continued to build our in-force block.”
Jon Stenberg, President and Chief Executive Officer
“Our announcement to invest in a modern technology ecosystem is an important step in Citizens' long-term growth strategy. By moving to third-party, cloud-based platforms, we are strengthening our insurance processing, underwriting, and policy administration capabilities.”
Jon Stenberg, President and Chief Executive Officer
Mach Natural Resources LP reported Q3 2026 financial results with total revenue of $319 million and net income of $10 million. The company averaged net production of 147 Mboe/d and declared a quarterly cash distribution of $0.22 per common unit. Management highlighted a disciplined reinvestment rate and plans to optimize the 2027 outlook around its Oswego oil play.
Term
Q3 2026
“Mach’s results are the reflection of a company built to deliver the highest possible cash distributions while maintaining a disciplined reinvestment rate, a lean cost structure and a strong balance sheet.”
Tom L. Ward, Chief Executive Officer
“The durable asset base we have built since 2018 through nearly two dozen disciplined acquisitions will continue to reward our unitholders. With 2.8 million acres and years of high-quality inventory across three world-class basins, we have optimized our 2027 plan around the favorable oil outlook.”
Redwire Corp reported 250,219,316 shares of common stock outstanding as of November 2, 2026. The filing highlights risks related to the integration of Edge Autonomy, reliance on U.S. government contracts, and the impact of macroeconomic conditions on its evolving space technology business.
Elicio Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided updates on its camupepimut clinical program. The company highlighted Phase 2 AMPLIFY-7P data in pancreatic cancer showing a 49% reduction in risk of recurrence or death in ctDNA-negative patients, which will inform its Phase 3 strategy.
“We are excited by the new Phase 2 AMPLIFY-7P findings in adjuvant PDAC, which provide encouraging direction and important insights as we advance camupepimut toward late-stage development and refine our Phase 3 strategy in adjuvant PDAC.”
Robert Connelly, President and Chief Executive Officer
“The 49% lower risk of disease recurrence or death among patients with undetectable ctDNA at baseline, alongside a 43% reduction in risk among ctDNA-positive patients, reinforces the encouraging clinical activity observed across both subgroups.”
Robert Connelly, President and Chief Executive Officer
Karat Packaging reported Q3 2026 net sales of $134.7 million, an 8.2% increase year-over-year, driven by strong e-commerce growth. However, net income fell to $4.7 million from $7.6 million due to pressure from elevated ocean freight costs and resin prices. The company is implementing price increases and diversifying its supply chain to Indonesia and South America to offset these costs.
Term
Q3 2026
“We delivered solid top-line growth in the third quarter, with sales increasing 8.2 percent, and we saw continued strong momentum in our e-commerce business, where online sales grew nearly 38 percent over the prior-year quarter.”
Alan Yu, Chief Executive Officer
“While increased import as well as domestic shipping costs and elevated resin prices pressured margin and contributed to results below our expectations, we remain encouraged by the strength of our sales performance, especially the continued momentum in our e-commerce business expansion.”
Phio Pharmaceuticals reported Q3 2026 financial results, highlighting a cash position of $10.6 million. The company achieved key milestones for its PH-762 program, including the completion of commercial-scale cGMP manufacturing and the submission of Phase 1b clinical data to the FDA in preparation for a Phase 2b study initiation expected in Q1 2027.
Term
Q3 2026
“We have successfully executed on critical development objectives to advance the PH-762 program toward Phase 2b study initiation. Commercial-scale drug substance manufacturing was completed and shipped to our drug product manufacturer in preparation for making clinical trial supply material. We have submitted detailed information to FDA providing final analysis of our Phase 1b clinical trial and the fundamentals of our intended upcoming Phase 2b study.”
Robert J. Bitterman, President and Chief Executive Officer
SiriusPoint reported Q3 2026 net income of $87 million and operating earnings per share of $0.88, representing a 19% increase. The company also announced a loss portfolio transfer (LPT) agreement with RiverStone to exit its remaining run-off reserves, which is expected to unlock over $200 million in capital.
Term
Q3 2026
“Our third quarter results represent continued strong performance, with our diversified, low-volatility portfolio again delivering on both growth and profitability. Our Insurance & Services segment grew by 20% and our core combined ratio was 90.1% both in the quarter and year to date.”
Scott Egan, Chief Executive Officer
“We have also announced another important milestone in the quarter linked to our legacy run-off portfolio, agreeing a loss portfolio transfer with RiverStone. This will allow us to effectively close the door on this historical book of reserves, further simplifying our business and unlocking significant capital.”
Coursera reported a significant revenue increase to $376.7 million for Q3 2026, driven largely by its merger with Udemy, which contributed to a substantial increase in total assets and common stock outstanding. Despite the growth, the company recorded a net loss of $25.6 million for the quarter, impacted by $30.8 million in merger and integration-related costs.
Exzeo Group, Inc. reported net income of $66.0 million for the nine months ended September 30, 2026, compared to $60.8 million in the prior year period. The company maintains a significant concentration of revenue from related parties, primarily HCI Group, Inc., and recently initiated share repurchase programs totaling $37.0 million.
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing camupepimut (ELI-002 7P) for adjuvant PDAC and other mKRAS-driven cancers. As of November 3, 2026, the company had 28,307,225 shares of common stock outstanding and is classified as a smaller reporting company and emerging growth company.
Peloton Interactive, Inc. reported its financial results for the first quarter of fiscal 2027, highlighting its ongoing restructuring initiatives and cost-saving measures. As of November 2, 2026, the company had approximately 430 million Class A and 15.8 million Class B shares outstanding, while continuing to focus on achieving future profitability and positive free cash flow.
Phio Pharmaceuticals Corp. reported a net loss of $12.3 million for the nine months ended September 30, 2026, compared to $6.3 million in the prior year period, primarily driven by a significant increase in research and development expenses. As of September 30, 2026, the company held $10.6 million in cash and cash equivalents, down from $21.0 million at the end of 2025.
Universal Electronics Inc. reported financial results for the third quarter ended September 30, 2026, highlighting a significant reduction in GAAP net loss to $0.3 million compared to $8.3 million in the prior year. The company saw strong growth in its connected home segment and generated $16.6 million in operating cash flow through the first nine months of the year.
Vaxart reported third quarter 2026 financial results and provided a business update, highlighting $65.5 million in cash and a runway into Q2 2027. The company expects topline data from its Phase 2b COVID-19 trial, involving approximately 5,400 participants, by mid-year 2027. Additionally, Vaxart expanded its norovirus vaccine IP with a new European patent and appointed Retired Vice Admiral Raquel C. Bono to its Board of Directors.
“During the third quarter, the Vaxart team worked diligently to advance our Phase 2b COVID-19 trial. The release of the topline efficacy and safety data from the main cohort remains a top priority, and we continue to actively work toward completion of analytical testing and disclosure of the trial results, in collaboration with our partner BARDA.”
HA Sustainable Infrastructure Capital Financial Results
HA Sustainable Infrastructure Capital reported Q3 2026 financial results with GAAP EPS of $1.04 and Adjusted EPS of $0.82, representing year-over-year growth. The company reaffirmed its long-term 2028 guidance for Adjusted EPS and ROE while highlighting a 27% increase in managed assets to $19.0 billion.
Term
Q3 2026
“Our team continues to execute on our business plan by adding new clients and deepening our relationships with existing ones, further diversifying into new asset classes, and optimizing our capital platform. These factors have translated into superb financial results through the first three quarters of 2026 with our Managed Assets increasing nearly $3 billion to $19 billion, Adjusted Recurring Net Investment Income growing 23% and Adjusted EPS by 15% year-to-date, and our Adjusted ROE rising to 15.6%.”
Jeffrey A. Lipson, President and Chief Executive Officer
“As much of the global economy has been adjusting to the increase in interest rates over the last few months, HASI continues to demonstrate the benefits of our business model in mitigating the impacts of a higher interest rate environment. Our new asset yields have increased to more than 11% year-to-date and we have continued to maintain our net investment margins. In combination with our growing base of management fees, we are generating greater profitability that is increasingly resilient to changes in the interest rate environment.”
Workiva Inc. reported third quarter 2026 financial results with total revenue of $263 million, a 17% increase year-over-year. The company achieved GAAP net income of $19 million ($0.35 per diluted share) and expanded its non-GAAP operating margin to 18.3% as it continues to leverage AI technology within its audit and compliance platform.
Term
Q3 2026
“AI is fundamentally changing enterprise software, from helping people do the work to increasingly doing the work itself. This shift plays directly to Workiva’s strengths. As software takes on more complex, regulated, and high-stakes work, the need for accuracy, transparency, and trust becomes even more critical. Workiva is uniquely positioned to meet these needs and expand the role our platform plays across the enterprise.”
Julie Iskow, President & Chief Executive Officer
“In Q3, we continued to deliver healthy top-line growth while expanding our operating margins, reinforcing that growth and profitability go hand-in-hand at Workiva. We beat the high end of our revenue guidance with 17% growth in both subscription and total revenue. At the same time, we expanded non-GAAP operating margin by 560 basis points year-over-year.”